These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 23169499)

  • 1. Improvement in progression-free survival in OCEANS bevacizumab arm: a critical point of view.
    Tomao F; Tomao S; Panici PB
    J Clin Oncol; 2013 Jan; 31(1):166-7. PubMed ID: 23169499
    [No Abstract]   [Full Text] [Related]  

  • 2. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
    Aghajanian C; Blank SV; Goff BA; Judson PL; Teneriello MG; Husain A; Sovak MA; Yi J; Nycum LR
    J Clin Oncol; 2012 Jun; 30(17):2039-45. PubMed ID: 22529265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Dhillon S
    BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.
    Burger RA; Brady MF; Rhee J; Sovak MA; Kong G; Nguyen HP; Bookman MA
    Gynecol Oncol; 2013 Oct; 131(1):21-6. PubMed ID: 23906656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controversy in treatment of advanced ovarian cancer.
    Scambia G; Salutari V; Amadio G
    Lancet Oncol; 2013 Sep; 14(10):920-1. PubMed ID: 23993374
    [No Abstract]   [Full Text] [Related]  

  • 6. Dose-dense effect: other contributors.
    Kesikli SA; Yuce D; Kilickap S
    Lancet Oncol; 2013 Nov; 14(12):e489. PubMed ID: 24176565
    [No Abstract]   [Full Text] [Related]  

  • 7. Dose-dense effect: other contributors - author's reply.
    Katsumata N
    Lancet Oncol; 2013 Nov; 14(12):e489-90. PubMed ID: 24176564
    [No Abstract]   [Full Text] [Related]  

  • 8. Transparency in interim monitoring.
    Freidlin B; Korn EL
    J Clin Oncol; 2014 Aug; 32(22):2387-8. PubMed ID: 24982465
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to B. Freidlin et al.
    Vergote I; Coens C; Casado A; Jimeno A
    J Clin Oncol; 2014 Aug; 32(22):2388. PubMed ID: 24982455
    [No Abstract]   [Full Text] [Related]  

  • 10. Primary surgery or neoadjuvant chemotherapy in ovarian cancer: what is the value of comparing apples with oranges?
    Vergote I; Leunen K; Amant F
    Gynecol Oncol; 2012 Jan; 124(1):1-2. PubMed ID: 22153125
    [No Abstract]   [Full Text] [Related]  

  • 11. Standardization of cytoreductive surgery is a precondition for clinical trials of ovarian cancer including cytoreductive surgery and/or neoadjuvant chemotherapy.
    Lim MC; Park SY
    Gynecol Oncol; 2012 May; 125(2):510. PubMed ID: 22266549
    [No Abstract]   [Full Text] [Related]  

  • 12. Bevacizumab in ovarian cancer: unanswered questions.
    Muggia F
    Drugs; 2012 May; 72(7):931-6. PubMed ID: 22564133
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to M.L. Friedlander et al.
    Colombo N
    J Clin Oncol; 2013 Jun; 31(18):2363. PubMed ID: 23930277
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to M.L. Friedlander et al.
    Spriggs DR
    J Clin Oncol; 2013 Jun; 31(18):2363. PubMed ID: 23930276
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: time to think differently?
    Friedlander ML; Stockler MR; Butow P; King MT; McAlpine J; Tinker A; Ledermann JA
    J Clin Oncol; 2013 Jun; 31(18):2362. PubMed ID: 23669225
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug development for chronic cancers: time to think differently?
    Spriggs DR
    J Clin Oncol; 2012 Nov; 30(31):3779-80. PubMed ID: 22987092
    [No Abstract]   [Full Text] [Related]  

  • 17. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.
    Roque DM; Ratner ES; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Nelson WK; Santin AD
    Gynecol Oncol; 2015 Jun; 137(3):392-400. PubMed ID: 25792179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer.
    Webber K; Friedlander M
    Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():126-138. PubMed ID: 28027849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies?
    Cheng X; Moroney JW; Levenback CF; Fu S; Jaishuen A; Kavanagh JJ
    J Chemother; 2009 Nov; 21(5):566-72. PubMed ID: 19933049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab rechallenge after first line maintenance bevacizumab.
    Konstantinopoulos PA; Berlin ST; Campos SM; Matulonis UA; Cannistra SA
    Gynecol Oncol; 2012 May; 125(2):510-1. PubMed ID: 22366591
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.